JPWO2020004675A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020004675A5 JPWO2020004675A5 JP2020527712A JP2020527712A JPWO2020004675A5 JP WO2020004675 A5 JPWO2020004675 A5 JP WO2020004675A5 JP 2020527712 A JP2020527712 A JP 2020527712A JP 2020527712 A JP2020527712 A JP 2020527712A JP WO2020004675 A5 JPWO2020004675 A5 JP WO2020004675A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- treatment
- week
- composition according
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023143451A JP7595719B2 (ja) | 2018-06-26 | 2023-09-05 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
| JP2024205093A JP2025028961A (ja) | 2018-06-26 | 2024-11-26 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690270P | 2018-06-26 | 2018-06-26 | |
| US62/690,270 | 2018-06-26 | ||
| US201862739386P | 2018-10-01 | 2018-10-01 | |
| US62/739,386 | 2018-10-01 | ||
| PCT/JP2019/026393 WO2020004675A1 (ja) | 2018-06-26 | 2019-06-26 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023143451A Division JP7595719B2 (ja) | 2018-06-26 | 2023-09-05 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020004675A1 JPWO2020004675A1 (ja) | 2021-07-15 |
| JPWO2020004675A5 true JPWO2020004675A5 (enExample) | 2022-03-03 |
| JP7345466B2 JP7345466B2 (ja) | 2023-09-15 |
Family
ID=68987235
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020527712A Active JP7345466B2 (ja) | 2018-06-26 | 2019-06-26 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
| JP2023143451A Active JP7595719B2 (ja) | 2018-06-26 | 2023-09-05 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
| JP2024205093A Pending JP2025028961A (ja) | 2018-06-26 | 2024-11-26 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023143451A Active JP7595719B2 (ja) | 2018-06-26 | 2023-09-05 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
| JP2024205093A Pending JP2025028961A (ja) | 2018-06-26 | 2024-11-26 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20210261963A1 (enExample) |
| EP (1) | EP3815696A4 (enExample) |
| JP (3) | JP7345466B2 (enExample) |
| KR (1) | KR20210023988A (enExample) |
| CN (1) | CN112399849A (enExample) |
| AU (2) | AU2019293687B2 (enExample) |
| BR (1) | BR112020026542A2 (enExample) |
| CA (1) | CA3101321A1 (enExample) |
| CL (1) | CL2020003367A1 (enExample) |
| CO (1) | CO2020015685A2 (enExample) |
| EC (1) | ECSP20083454A (enExample) |
| IL (1) | IL279692A (enExample) |
| MX (2) | MX2020013880A (enExample) |
| MY (1) | MY209148A (enExample) |
| NZ (1) | NZ770540A (enExample) |
| PE (1) | PE20210630A1 (enExample) |
| PH (1) | PH12020552078A1 (enExample) |
| SG (1) | SG11202011554PA (enExample) |
| TW (1) | TW202035692A (enExample) |
| WO (1) | WO2020004675A1 (enExample) |
| ZA (1) | ZA202007682B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113748209A (zh) | 2019-02-27 | 2021-12-03 | 斯托克制药公司 | 用于治疗病况和疾病的反义寡聚体 |
| AU2021270720A1 (en) | 2020-05-11 | 2022-12-08 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| IL307937A (en) | 2021-04-30 | 2023-12-01 | Sarepta Therapeutics Inc | Treatment methods for muscular dystrophy |
| JP2025509438A (ja) | 2022-03-17 | 2025-04-11 | サレプタ セラピューティクス， インコーポレイテッド | ホスホロジアミデートモルホリノオリゴマーコンジュゲート |
| AU2024222908A1 (en) * | 2023-02-14 | 2025-09-04 | Stoke Therapeutics, Inc. | Antisense oligomer formulations |
| US20240368596A1 (en) * | 2023-05-05 | 2024-11-07 | Biomarin Pharmaceutical Inc. | Dystrophin exon skipping oligonucleotides |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69033986T2 (de) | 1989-12-20 | 2003-03-13 | Antivirals Inc., Portland | Ungeladene, auf Morpholin basierende Polymere mit Chiralen, Phosphor enthaltenden Brücken zwischen den Untereinheiten |
| EP2530155B1 (en) | 2002-11-25 | 2016-03-16 | Masafumi Matsuo | ENA nucleic acid drugs modifying splicing in mRNA precursor |
| SI2206781T1 (sl) | 2004-06-28 | 2016-05-31 | The University Of Western Australia | Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe |
| WO2006038608A1 (ja) | 2004-10-05 | 2006-04-13 | Nippon Shinyaku Co., Ltd. | オリゴ二本鎖ｒｎａ及び医薬組成物 |
| US20090069260A1 (en) | 2005-05-30 | 2009-03-12 | Nippon Shinyaku Co., Ltd | Method for producing a nucleic-acid-containing complex preparation |
| CA2884340C (en) | 2007-11-15 | 2017-07-25 | Sarepta Therapeutics, Inc. | Method of synthesis of morpholino oligomers |
| US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
| EP2762567B1 (en) | 2008-10-24 | 2016-07-13 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for DMD |
| TWI541024B (zh) * | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| ES2907250T3 (es) * | 2012-01-27 | 2022-04-22 | Biomarin Tech Bv | Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker |
| KR20230074606A (ko) * | 2013-03-14 | 2023-05-30 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이영양증의 치료를 위한 엑손 스키핑 조성물 |
| NZ732507A (en) | 2013-03-15 | 2018-08-31 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
| CN105228999B (zh) * | 2013-05-24 | 2021-03-02 | 味之素株式会社 | 吗啉代寡核苷酸的制备方法 |
| WO2017059131A1 (en) * | 2015-09-30 | 2017-04-06 | Sarepta Therapeutics, Inc. | Methods for treating muscular dystrophy |
| FR3044926B1 (fr) * | 2015-12-09 | 2020-01-31 | Genethon | Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine |
-
2019
- 2019-06-26 CN CN201980043482.XA patent/CN112399849A/zh active Pending
- 2019-06-26 US US17/253,760 patent/US20210261963A1/en not_active Abandoned
- 2019-06-26 BR BR112020026542-0A patent/BR112020026542A2/pt unknown
- 2019-06-26 KR KR1020217001037A patent/KR20210023988A/ko not_active Ceased
- 2019-06-26 JP JP2020527712A patent/JP7345466B2/ja active Active
- 2019-06-26 PE PE2020002157A patent/PE20210630A1/es unknown
- 2019-06-26 MY MYPI2020006568A patent/MY209148A/en unknown
- 2019-06-26 AU AU2019293687A patent/AU2019293687B2/en active Active
- 2019-06-26 TW TW108122381A patent/TW202035692A/zh unknown
- 2019-06-26 NZ NZ770540A patent/NZ770540A/en unknown
- 2019-06-26 SG SG11202011554PA patent/SG11202011554PA/en unknown
- 2019-06-26 WO PCT/JP2019/026393 patent/WO2020004675A1/ja not_active Ceased
- 2019-06-26 EP EP19826094.5A patent/EP3815696A4/en active Pending
- 2019-06-26 CA CA3101321A patent/CA3101321A1/en active Pending
- 2019-06-26 MX MX2020013880A patent/MX2020013880A/es unknown
-
2020
- 2020-12-02 PH PH12020552078A patent/PH12020552078A1/en unknown
- 2020-12-09 ZA ZA2020/07682A patent/ZA202007682B/en unknown
- 2020-12-14 CO CONC2020/0015685A patent/CO2020015685A2/es unknown
- 2020-12-16 MX MX2025001486A patent/MX2025001486A/es unknown
- 2020-12-22 IL IL279692A patent/IL279692A/en unknown
- 2020-12-23 EC ECSENADI202083454A patent/ECSP20083454A/es unknown
- 2020-12-23 CL CL2020003367A patent/CL2020003367A1/es unknown
-
2023
- 2023-09-05 JP JP2023143451A patent/JP7595719B2/ja active Active
- 2023-11-08 US US18/504,781 patent/US20240158792A1/en active Pending
-
2024
- 2024-11-26 JP JP2024205093A patent/JP2025028961A/ja active Pending
-
2025
- 2025-12-19 AU AU2025283628A patent/AU2025283628A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020004675A5 (enExample) | ||
| JP3701870B2 (ja) | 末梢血管疾患治療のための９−デオキシ−２’，９−α−メタノ−３−オキサ−４，５，６−トリノール−３，７−（１’，３’−インターフェニ | |
| JP2020189864A5 (enExample) | ||
| EP3718561A1 (en) | Therapeutic agent for inflammatory bowel disease | |
| JP2017510624A5 (enExample) | ||
| KR20200089656A (ko) | 트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법 | |
| CA2923685A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| CA3019769C (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| BRPI0708347A2 (pt) | inibição jak2 como um tratamento da hipertensão arterial pulmonar | |
| JP2016516773A5 (enExample) | ||
| JPWO2013118773A1 (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
| HRP20201696T1 (hr) | Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu | |
| CN120302976A (zh) | 用于治疗神经肌肉病状的哒嗪酮组合物 | |
| KR20080016608A (ko) | 구강 투여용 아포모르핀의 약제학적 조성물 | |
| JPH01153689A (ja) | 抗パーキンソン病エルゴリン誘導体 | |
| US10052281B2 (en) | Local administration-type pharmaceutical for improving dysphagia | |
| JPWO2019232130A5 (enExample) | ||
| RU2021101447A (ru) | Композиция, содержащая антисмысловой олигонуклеотид, и ее применение для лечения мышечной дистрофии дюшенна | |
| RU2023117173A (ru) | Композиция, содержащая антисмысловой олигонуклеотид, и ее применение для лечения мышечной дистрофии дюшенна | |
| EP2982382A1 (en) | Compounds for preventing ototoxicity | |
| US9974768B2 (en) | Pharmaceutical for improving dysphagia | |
| EP3954374A1 (en) | Pharmaceutical combination of pimozide and methotrexate and use thereof | |
| US20090012036A1 (en) | Stable S-adenosyl-L-methionine | |
| US11364218B2 (en) | Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome | |
| US20250064758A1 (en) | Antivirals targeting phosphatidic acid phosphatase (pap) |